Cardiac Surgery Unit, ASST San Gerardo Hospital, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Cardiac Surgery Unit, ASST San Gerardo Hospital, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
J Thorac Cardiovasc Surg. 2019 Jul;158(1):141-151. doi: 10.1016/j.jtcvs.2018.12.078. Epub 2019 Jan 11.
Long-term survival benefits of full arterial revascularization with radial artery (RA) used in addition to bilateral internal mammary arteries (BIMA) compared with saphenous vein (SV) used in addition to BIMA has not been clearly defined.
We retrospectively analyzed 660 3-vessel coronary artery disease subjects who received BIMA in addition to either RA (n = 206) or SV (n = 454) grafting in a period between June 1999 and November 2017. After propensity score matching, we obtained 190 matched pairs for analysis.
In the matched population, in-hospital mortality occurred in 4 patients (1%), with 2 deaths (1.1%) in the BIMA + RA group and 2 deaths (1.1%) in BIMA + SV group (P > .99). The median follow-up time was 9.2 years (interquartile range, 5.6-13 years) with a maximum follow-up time of 18.5 years. There was not a significant difference in long-term survival between the 2 groups over the follow-up period. Survival at 5, 10, and 15 years were 94.8 ± 1.7%, 83.7 ± 3.1%, and 78.6 ± 3.9% in the BIMA + RA group and 96.2 ± 1.4%, 85.1 ± 2.9%, and 80.4 ± 3.6% in the BIMA + SV group (stratified log-rank P = .78). Cox proportional hazard regression model was used to estimate that the use of RA in addition to BIMA did not affect the late mortality (propensity score adjusted hazard ratio, 1.05; 95% confidence interval, 0.62-1.79; P = .83).
In a relatively small population of triple-vessel coronary artery disease, the use of RA as a third arterial conduit with BIMA did not confer a long-term survival benefit.
与同时使用大隐静脉(SV)和双侧内乳动脉(BIMA)相比,额外使用桡动脉(RA)进行全动脉血运重建对长期生存的益处尚未明确界定。
我们回顾性分析了 1999 年 6 月至 2017 年 11 月期间接受 BIMA 加 RA(n=206)或 SV(n=454)搭桥治疗的 660 例 3 支血管病变患者。通过倾向评分匹配,我们获得了 190 对匹配的患者进行分析。
在匹配人群中,住院期间死亡 4 例(1%),BIMA+RA 组 2 例(1.1%),BIMA+SV 组 2 例(1.1%)(P>.99)。中位随访时间为 9.2 年(四分位距,5.6-13 年),最长随访时间为 18.5 年。在随访期间,两组之间的长期生存率无显著差异。BIMA+RA 组 5、10 和 15 年的生存率分别为 94.8±1.7%、83.7±3.1%和 78.6±3.9%,BIMA+SV 组分别为 96.2±1.4%、85.1±2.9%和 80.4±3.6%(分层对数秩检验 P=0.78)。使用 Cox 比例风险回归模型估计,BIMA 加 RA 的使用并未影响晚期死亡率(倾向评分调整后的风险比,1.05;95%置信区间,0.62-1.79;P=0.83)。
在一个相对较小的三支血管病变人群中,使用 RA 作为 BIMA 的第三种动脉移植物并没有带来长期生存获益。